Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioorg Med Chem ; 20(1): 498-509, 2012 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-22100260

RESUMEN

This paper describes our recent efforts to design and synthesise potent and selective PDE5 inhibitors and the use of in vitro predictors of clearance, absorption and permeability to maximise the potential for dose-proportional pharmacokinetics and good oral bioavailability in man. Optimisation of the preclinical profile resulted in the identification of UK-369003 (19a) and its nomination as a clinical candidate. The clinical pharmacokinetic and safety profile has enabled us to progress the compound to test its efficacy in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and a paper describing its efficacy has recently been published.


Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/química , Inhibidores de Fosfodiesterasa 5/química , Inhibidores de Fosfodiesterasa 5/farmacocinética , Pirimidinonas/química , Pirimidinonas/farmacocinética , Sulfonamidas/química , Sulfonamidas/farmacocinética , Administración Oral , Disponibilidad Biológica , Línea Celular , Fosfodiesterasas de Nucleótidos Cíclicos Tipo 5/metabolismo , Evaluación Preclínica de Medicamentos , Activación Enzimática/efectos de los fármacos , Humanos , Síntomas del Sistema Urinario Inferior/tratamiento farmacológico , Síntomas del Sistema Urinario Inferior/etiología , Masculino , Inhibidores de Fosfodiesterasa 5/farmacología , Hiperplasia Prostática/complicaciones , Pirimidinonas/farmacología , Sulfonamidas/farmacología
3.
ACS Med Chem Lett ; 6(6): 650-4, 2015 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-26101568

RESUMEN

Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain. Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chemical matter that is efficacious in preclinical models of neuropathic and inflammatory pain.

4.
Bioorg Med Chem Lett ; 16(4): 905-10, 2006 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-16290934

RESUMEN

A series of zwitterionic delta-opioid agonists, with targeted physicochemistry, as a strategy to limit potential for CNS exposure, were prepared. These agents were found to possess exquisite potency and selectivity over mu and kappa-opiate activity. Furthermore, analogue 3a was found to display restricted CNS exposure, as evidenced by its inactivity in a rodent hyperlocomotion assay of central opiate activity. Dog pharmacokinetic studies on 3a indicated encouraging oral bioavailability.


Asunto(s)
Indoles/farmacología , Isoquinolinas/farmacología , Receptores Opioides delta/agonistas , Animales , Perros , Diseño de Fármacos , Indoles/administración & dosificación , Indoles/síntesis química , Isoquinolinas/administración & dosificación , Isoquinolinas/síntesis química , Ratones , Conformación Molecular , Peso Molecular , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA